
Opinion|Videos|July 11, 2024
Clinical Utilization of TROP2-Directed Antibody-Drug Conjugates
Author(s)Aditya Bardia, MD, MPH, Laura Huppert, MD
Medical oncologists share clinical practices for selecting and sequencing TROP2-directed antibody-drug conjugates, highlighting ideal candidates for sacituzumab govitecan or datopotamab deruxtecan.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- What insights and perspectives can you provide on the use of TROP2-directed antibody-drug conjugates from your practice?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
Managing Toxicity and Safety of Belzutifan in ccRCC
3
Spotlighting Sequencing and Biomarkers in Bladder Cancer Management
4
Dr Shubham Pant Highlights Progress and Promise in Pancreatic Cancer Treatment
5




















